课题基金 / 基金详情

项目摘要

项目成果

JEFFREY B KAPLAN的其他基金

相似基金

相关文献

中文摘要
翻译
对《项目摘要/摘要》进行了修改,以反映上述变化:与植入式医疗器械相关的一个主要风险是其高感染率。居住在医疗器械上的细菌形成了包裹在基质中的生物膜,这些生物膜抵抗抗菌治疗,而且往往很难或不可能根除。金黄色葡萄球菌和表皮葡萄球菌的细胞外基质是最常见的设备相关病原体,它含有一种名为PNAG(聚乙酰氨基葡萄糖)的粘性多糖,它介导表面附着、细胞间黏附、抗杀菌剂和免疫逃避。我们实验室发现了一种能降解PNAG的酶(分散剂B)。初步研究表明,分散素B抑制葡萄球菌生物膜的形成,分离预先形成的葡萄球菌生物膜,并使葡萄球菌生物膜细胞对体外抗菌药物的杀伤敏感。我们的假设是,分散素B将是一种临床上有用的抗生物被膜剂,用于治疗和预防体内葡萄球菌生物被膜感染。本方案的目的是证明分散素B与抗生素协同作用,在体外分离和杀死金黄色葡萄球菌和表皮葡萄球菌生物膜。分散素B将在模拟的每日抗生素导管锁定试验中进行溶液测试,并在抗感染设备涂层的模型中单独或与抗生素一起加载到聚亚安酯磁盘上。我们计划测试的抗生素包括替吉环素和万古霉素。这些研究结果将扩大我们对PNAG介导的生物被膜耐药机制的认识,并将证明在体内使用分散剂B作为抗生物被膜药物的可行性。由于分散在B中不会杀死细菌或抑制它们的生长,因此以B为基础的分散策略可能比使用传统抗生素的策略更不容易产生耐药性。
英文摘要
The Project Summary/Abstract was modified to reflect the changes described above: A major risk associated with implanted medical devices is their high rate of infection. Bacteria that colonize medical devices form matrix-encased biofilms that resist antimicrobial therapy and are often difficult or impossible to eradicate. The extracellular matrix of Staphylococcus aureus and Staphylococcus epidermidis, the most common device-associated pathogens, contains a sticky polysaccharide named PNAG (poly-N-acetylglucosamine) that mediates surface attachment, intercellular adhesion, biocide resistance and immune evasion. Our laboratory discovered an enzyme (dispersin B) that degrades PNAG. Preliminary studies indicate that dispersin B inhibits staphylococcal biofilm formation, detaches pre-formed staphylococcal biofilms, and sensitizes staphylococcal biofilm cells to antimicrobial killing in vitro. Our hypothesis is that dispersin B will be a clinically useful anti-biofilm agent for the treatment and prevention of staphylococcal biofilm infections in vivo. The goal of the present proposal is to demonstrate that dispersin B acts synergistically with antibiotics to detach and kill S. aureus and S. epidermidis biofilms in vitro. Dispersin B will be tested both in solution in a simulated daily antibiotic catheter lock assay, and loaded onto polyurethane disks, either alone or in combination with antibiotics, in a model for antiinfective device coatings. The antibiotics that we plan to test include tigecycline and vancomycin. The results of the proposed studies will extend our knowledge about the mechanism of PNAGmediated biofilm resistance to specific antibiotics, and will demonstrate the feasibility of using dispersin B as anti-biofilm agent in vivo. Since dispersin B does not kill bacteria or inhibit their growth, dispersin B-based strategies may be less prone to the evolution of resistance than strategies utilizing conventional antibiotics.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Characterization of TEM-1 β-Lactamase-Producing Kingella kingae Clinical Isolates.
TEM-1 β-内酰胺酶生产 Kingella kingae 临床分离株的表征。
DOI: 10.1128/aac.00318-13
发表时间: 2013
期刊: Antimicrobial agents and chemotherapy
影响因子: 4.9
作者: [Banerjee,Anushree, Kaplan,JeffreyB, Soherwardy,Amenah, Nudell,Yoav, Mackenzie,GraceA, Johnson,Shannon, Balashova,NataliyaV]
通讯作者: Balashova,NataliyaV
DOI: 10.1038/ja.2011.113
发表时间: 2012-02
期刊: The Journal of antibiotics
影响因子: --
作者: []
通讯作者:
DOI: 10.1111/j.1462-2920.2012.02810.x
发表时间: 2013-02
期刊: Environmental microbiology
影响因子: 5.1
作者: [Rendueles O, Kaplan JB, Ghigo JM]
通讯作者: Ghigo JM
DOI: 10.1016/j.resmic.2011.03.008
发表时间: 2011-06
期刊: RESEARCH IN MICROBIOLOGY
影响因子: 2.6
作者: [Kaplan, Jeffrey B., Jabbouri, Said, Sadovskaya, Irina]
通讯作者: Sadovskaya, Irina
Biofilm matrix-degrading enzymes for the treatment and prevention of S. aureus-as
Biofilm matrix-degrading enzymes for the treatment and prevention of S. aureus-as
  • 批准号:
    8658802
  • 项目类别:
  • 资助金额:
    $17.68万
  • 财政年份:
    2012
  • 负责人:
    JEFFREY B KAPLAN
  • 依托单位:
Biofilm matrix-degrading enzymes for the treatment and prevention of S. aureus-as
  • 批准号:
    8450727
  • 项目类别:
  • 资助金额:
    $15.03万
  • 财政年份:
    2012
  • 负责人:
    JEFFREY B KAPLAN
  • 依托单位:
Biofilm matrix-degrading enzymes for the treatment and prevention of S. aureus-as
  • 批准号:
    8608900
  • 项目类别:
  • 资助金额:
    $12.99万
  • 财政年份:
    2012
  • 负责人:
    JEFFREY B KAPLAN
  • 依托单位:
海外基金